Meeting
2023 ASCO Annual Meeting
Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial.
Authors
Mirella Nardo
University of Texas MD Anderson Cancer Center, Houston, TX
Mirella Nardo , Matthew Reilley , Amadeo Biter , JoAnn Lim , Stacie A. Bean , Ly Minh Nguyen , Priya Bhosale , Casey Ager , Coline A Couillault , Sarina A. Piha-Paul , Siqing Fu , Apostolia Maria Tsimberidou , Timothy A. Yap , Aung Naing , Jordi Rodon Ahnert , Vivek Subbiah , Daniel D. Karp , Michael A. Curran , David S. Hong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immunobiology
Clinical Trial Registration Number
NCT0266877
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2564)
DOI
10.1200/JCO.2023.41.16_suppl.2564
Abstract #
2564
Poster Bd #
406
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk
Poster
2021 ASCO Annual Meeting
A phase I study of an IDO inhibitor (SHR9146) plus camrelizumab and in combination with/without apatinib in patients with advanced solid tumors: Safety and efficacy analysis.
First Author: Ying Cheng
Poster
2019 ASCO Annual Meeting
Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors.
First Author: Matthew Reilley
Poster
2019 ASCO Annual Meeting
A phase I study evaluating COM701 in patients with advanced solid tumors.
First Author: Drew W. Rasco